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Background
We sought to evaluate whether oral immunotherapy
(OIT) is safe and efficacious in desensitizing children
with cow’s milk allergy (CMA).
Methods
We study 23 children with CMA that met the following
criteria: clinical history of IgE-mediated CMA in the last
6 months and specific IgE (sIgE) for cow’s milk (CM) ≥
15 kU/L (> 2 years) or ≥ 5 kU/L (< 2 years). On study
entry, basal serum levels for sIgE for CM and casein
plus sIgG4 for casein were obtained. The study was
divided into 2 stages. In the first 12 months, patients
were randomly assigned in a double-blind manner to pla-
cebo or active OIT. At the end of the first 12 months
period, patients submitted to milk double-blind placebo-
controlled food challenge (DBPCFC). The study was
unblinded in this time and patients on the placebo group
started on a 24 months active OIT period. Children on
active OIT completed 12 more months of treatment. sIgE
for CM and casein and sIgG4 for casein were obtained
throughout the study.
Results
15 children completed treatment: 11 in the active group
and 4 in the control. The median frequency for total reac-
tions in active group was 56,6% versus 19,4% in the placebo
group (p < 0,05). At the end of the first 12 months period,
the test group reacted with an average of 10 g of whole
milk in DBPCFC versus 4.1 g in the placebo group (p >
0.05). After 12 months active OIT period, 4 patients had a
negative challenge, and after 24 months 3 more patients
had a negative challenge. Among the 6 participants who
reacted, there was an increase an average of 5,2 g dose
threshold to cause reactions to milk during the period
between 12 and 24 months of treatment. There was an
increase in the frequency of symptoms to the average dose
of 1,9 g, with subsequent decrease. In cases who tolerated
12 months, there was a significant increase of sIgG4 for
casein at 12 months from baseline, compared to non-
tolerant. The evolution of serum levels over time, by
adjusting the graphs of smoothing, showed a reduction of
sIgE for CM and casein at 24 months and an increase of
sIgG4 for casein in the first 12 months.
Conclusions
Milk OIT seems to be effective in the induction of clini-
cal desensitization and immunomodulation in children
with CMA, but the risk-benefits should be weighed.
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